EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia

Asli Odabasi Giden, Duzgun Ozatli, Mehmet Ali Erkurt, Abdullah Karakus, Gulden Sincan, Fehmi Hindilerden, Yusuf Bilen, Ugur Hatipoglu, Gulsum Akgun Cagliyan, Tuba Hacibekiroglu, Sinan Demircioglu, Didar Yanardag Acik und 12 weitere

Hemato · 15.05.2026 · 7 (2) · 16

DOI: 10.3390/hemato7020016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, online erschienen am 15.05.2026. Verfasst von Asli Odabasi Giden und 23 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous disease characterized by variable clinical outcomes. The introduction of targeted therapies, particularly the BCL-2 inhibitor venetoclax, has significantly improved treatment outcomes in patients with relapsed/refractory (R/R) CLL. However, real-world data on the safety and effectiveness of venetoclax-based regimens remain limited.

Methods

In this multicenter retrospective study, 147 adult patients with R/R CLL treated with venetoclax between April 2019 and August 2025 were analyzed. Venetoclax was administered as monotherapy or in combination with rituximab, obinutuzumab, or ibrutinib. Adverse events were graded according to CTCAE v4.0, and treatment responses were assessed based on IWCLL criteria. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were evaluated using Kaplan–Meier analysis.

Results

The median age at venetoclax initiation was 64 years, and patients had received a median of two prior lines of therapy. Combination therapy was administered in 78.9% of patients. The overall response rate was 83.0%, including complete remission in 65.3% of patients. Grade ≥ 3 hematologic adverse events included neutropenia (18.4%), thrombocytopenia (14.3%), and anemia (7.5%). Tumor lysis syndrome (TLS) occurred in 28.6% of patients, predominantly during the dose ramp-up phase. At a median follow-up of 61 months, median OS and PFS were both 60 months. Bulky disease was associated with inferior survival outcomes.

Conclusions

Venetoclax-based therapy is effective and well tolerated in patients with R/R CLL in a real-world setting. High response rates and durable survival outcomes were observed despite the inclusion of patients with high-risk clinical and biological features. These findings support the use of venetoclax as a key component of modern CLL treatment strategies and highlight the importance of real-world evidence in optimizing patient management.

Zitieren

APA

Giden, A. O., Ozatli, D., Erkurt, M. A., Karakus, A., Sincan, G., Hindilerden, F., Bilen, Y., Hatipoglu, U., Cagliyan, G. A., Hacibekiroglu, T., Demircioglu, S., Acik, D. Y., Demir, C., Katircilar, Y., Tombak, A., Yilmaz, S., Kuku, I., Erdem, F., Ozturkmen, A. Y., …, & Altuntas, F. (2026). Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemato, 7(2), 16. https://doi.org/10.3390/hemato7020016

Vancouver

Giden AO, Ozatli D, Erkurt MA, Karakus A, Sincan G, Hindilerden F, et al. Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemato. 2026;7(2):16. doi:10.3390/hemato7020016

BibTeX
@article{Giden2026,
  author = {Giden, Asli Odabasi and Ozatli, Duzgun and Erkurt, Mehmet Ali and Karakus, Abdullah and Sincan, Gulden and Hindilerden, Fehmi and Bilen, Yusuf and Hatipoglu, Ugur and Cagliyan, Gulsum Akgun and Hacibekiroglu, Tuba and Demircioglu, Sinan and Acik, Didar Yanardag and Demir, Cengiz and Katircilar, Yavuz and Tombak, Anil and Yilmaz, Seda and Kuku, Irfan and Erdem, Fuat and Ozturkmen, Asli Yuksel and Dal, Mehmet Sinan and Basci, Semih and Korkmaz, Serdal and Ulas, Turgay and Altuntas, Fevzi},
  title = {Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia},
  journal = {Hemato},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {16},
  doi = {10.3390/hemato7020016}
}
Kostenlos starten →